Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Imaging of [Tc-99m]-RPI-T-087 in Knee Osteoarthritis
NCT03503825Phase 1Unknown
- Sponsor
- Reiley Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [Tc-99m]-RPI-T-087 in knee osteoarthritis (OA) (2 arms), sponsored by Reiley Pharmaceuticals. Primary endpoint: Incidence of treatment emergent adverse events at 3 days. Status: unknown.
02
Drugs
[Tc-99m]-RPI-T-087
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03503825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503825.